A recent clinical trial of a virotherapy approach, consisting of an engineered poliovirus, has provided evidence of apparently durable responses in patients with recurrent glioblastoma. The results of this trial and others indicate that virotherapy might be an effective tool in anticancer immunotherapy. Yet, caution must be exercised until appropriately powered randomized clinical trials truly show efficacy.
This is a preview of subscription content, log in via an institution to check access.
References
McGranahan, N. & Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15–26 (2015).
Lawler, S. E. et al. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 3, 841–849 (2017).
Lang, F. F. et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J. Clin. Oncol. 36, 1419–1427 (2018).
Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119 (2017).
Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150–161 (2018).
Brown, M. C. et al. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci. Transl Med. 9, eaan4220 (2017).
Chiocca, E. A. et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. 10, 958–966 (2004).
Cloughesy, T. F. et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci. Transl Med. 8, 341ra375 (2016).
Wheeler, L. A. et al. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro Oncol. 18, 1137–1145 (2016).
Markert, J. M. et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol. Ther. 22, 1048–1055 (2014).
Acknowledgements
E.A.C. acknowledges research support by the US NIH National Cancer Institute under awards 2P01CA163205, CA069246-20, and P50CA165962. P.P. acknowledges research support by the US National Institute of Neurological Disorders and Stroke under award 5K08NS101091. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.A.C. is a consultant for Advantagene and DNAtrix. He has also previously been a consultant for Tocagen and Ziopharm Oncology. P.P. declares no competing interests.
Additional information
Related link
The ClinicalTrials.gov database: www.clinicaltrials.gov
Rights and permissions
About this article
Cite this article
Peruzzi, P., Chiocca, E.A. Viruses in cancer therapy — from benchwarmers to quarterbacks. Nat Rev Clin Oncol 15, 657–658 (2018). https://doi.org/10.1038/s41571-018-0077-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0077-0
- Springer Nature Limited
This article is cited by
-
An engineered virus shows potential as an immune therapy in glioblastoma
Nature (2023)
-
Clinical trial links oncolytic immunoactivation to survival in glioblastoma
Nature (2023)
-
Current State of Immunotherapy for Treatment of Glioblastoma
Current Treatment Options in Oncology (2019)